Please assess the completion status of the following clinical trial:

Trial Title: Probiotic Visbiome for Inflammation and Translocation in HIV Ι

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented HIV-1 infection~* Male adult (age \>18 years)~* Antiretroviral therapy-naïve~* Ability to provide informed consent~* HIV-1 viral load ≥1,000 copies/ml~Exclusion Criteria:~* Current alcohol or substance use judged by the Investigator to potentially interfere with participant study compliance~* Taking pharmaceutical grade probiotics~* Any of the following abnormal laboratory results in screening:~  * Hemoglobin \<85 g/L~ * Neutrophil count \<750 cells/μl~ * Platelet count \<50,000 cells/μl~ * AST or ALT \>5X the upper limit of normal~* Malignancy~* Colitis~* Liver fibrosis (decompensated cirrhosis), portal hypertension or clinical hepatitis~* Other significant underlying disease (non-HIV-1) that might impinge upon disease progression or death

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Probiotic Group (Type: EXPERIMENTAL): Visbiome experimental group (900 billion bacteria daily; 2 sachets daily)
- Placebo Group (Type: PLACEBO_COMPARATOR): Placebo comparator group

Based on this trial design, predict the completion outcome and termination type (if applicable).